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ABSTRACT
Data on all outpatient opioid prescriptions (N=71,647) to youth below age 21 (N=42,020)
from 2005-2016 were extracted from electronic medical records within a university
hospital system, including demographic characteristics, markers of morbidity, and
mortality. Relative risk was calculated for markers of morbidity and mortality based on
sociodemographic characteristics. The sample was primarily male (55.0%),
Hispanic/Latino (50.1%), English-speaking (88.9%), and publicly insured(50.1%). Mean
age was 13.54 (sd = 6.50). From 2005-2016, overall frequency of opioid prescriptions
increased by 86.6% (from 2470 to 4610) with the largest increase (206.2%) observed
from 2005-2008 (2470 to 7562). Patients who were older, White, and Non-Hispanic were
more likely to receive multiple opioid prescriptions. Large increases in opioid-related
morbidity and mortality were documented, although base-rates remained low.
Significantly increased risk of adverse outcomes was observed in patients receiving
multiple opioid prescriptions, and in patients who were older, of minority race, and
publicly insured or uninsured.
.
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Chapter 1
Introduction
Problematic opioid use and subsequent adverse consequences, including opioid-related
overdose deaths, are well-documented public health concerns in the United States (US).
These concerns are partially fueled by the dramatic increase in rates of opioid
prescriptions and community availability of prescription opioids over recent decades
(Manchikanti, Fellows, Ailinani, & Pampati, 2010; Shaheed, Maher, Williams, Day, &
Mclachlan, 2016; Vowles et al., 2015). In adults, drug overdose is the leading cause of
accidental death, whereby 60-70% of prescription drug overdose deaths can be accounted
for by prescribed opioids (Centers for Disease Control and Prevention National Center
for Health Statistics, 2015; Jones, Mack, & Paulozzi, 2013; Rudd, Aleshire, Zibbell, &
Gladden, 2016; Vowles et al., 2015) and opioid-related overdose deaths are decreasing
the life expectancy of Americans (Kochanek, Murphy, Xu, & Arias, 2017). Further,
opioid misuse, defined as “opioid use contrary to the directed or prescribed pattern of use,
regardless of the presence or absence of harm or adverse effects” (Vowles et al., 2015, p.
570) is associated with increased heroin use (Carlson, Nahhas, Martins, & Daniulaityte,
2016) among other adverse consequences (e.g. overdose).
While these issues are relatively well characterized in adults, opioid prescribing
trends and implications remain unclear in children, adolescents, and young adults
(Schechter, 2014). Results from published national studies examining opioid prescribing
rates to youth in the last two decades vary greatly, with some data indicating little to no
significant change (Groenewald, Rabbitts, Gebert, & Palermo, 2015), while others report
increases of 40%-100% (Fortuna, Robbins, Caiola, Joynt, & Halterman, 2010; Mazer-
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Amirshahi, Mullins, Rasooly, van den Anker, & Pines, 2014; Sheridan et al., 2016).
Nonetheless, opioids are a part of standard treatment for painful conditions in youth, such
as traumatic injuries, post-surgical pain management, cancer, and dental care
(Groenewald et al., 2015; Walco, Gove, Phillips, & Weisman, 2017).
Although prescription trends in youth are uncertain, two things are clear; both of
which shadow trends in adults: 1) youth are misusing opioids, and 2) problematic opioid
use among youth is associated with substantial risk of morbidity and mortality. In 2016,
1.7% of persons age 12 or older initiated illicit drug use with pain relievers, which was
more than initiation rates of all other illicit drugs, aside from marijuana (Substance Abuse
and Mental Health Services Administration, 2017). Findings from the 2015 National
Survey on Drug Use and Health revealed that pain relievers, typically opioids, were the
most widely used psychotherapeutic drug among persons above the age of 12 (Center for
Behavioral Health Statistics and Quality, 2016), with leftover prescriptions repeatedly
identified as a primary source for nonmedical use (Binswanger & Glanz, 2015; McCabe,
West, & Boyd, 2013a; Voepel-Lewis, Wagner, & Tait, 2015). More specifically, in 2016,
approximately 3.6% of adolescents (n~891,000 age 12 to 17 years) and 7.3% of young
adults (n=~2.5 million age 18 to 25) reported current misuse of prescription pain
relievers. Further, it is estimated that .6% of adolescents and 1.1% of young adults had an
opioid use disorder in 2016 (Substance Abuse and Mental Health Services
Administration, 2017).
Nonmedical use of prescription opioids in childhood has also been identified as a
strong predictor of initiating heroin use during adolescence (Cerdá, Santaella, Marshall,
Kim, & Martins, 2015; Palamar, Shearston, Dawson, Mateu-Gelabert, & Ompad, 2016).
Of greater concern, deaths from prescription drug overdoses in youth doubled from 2001
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to 2014 (Center for Disease Control & National Center for Health Statistics, 2015), as did
inpatient admissions due to opioid poisoning from 1997 to 2012 (Gaither, Leventhal,
Ryan, & Camenga, 2016). In 2015, drug-related death rates for youth age 15-19 in the
United States was highest for opioids, especially heroin (Curtain, Tejada-Vera, &
Warner, 2017). Recent data also reflect an association between national rates of opioid
prescribing to adolescents and rates of adolescent calls to poison centers regarding opioid
ingestions (Sheridan et al., 2016).
Further, evidence has shown that adolescents tend to underestimate the potential
risk of taking prescription opioids (Martin, Bhalla, Beltran, Veneziano, & Tobias, 2014),
with one study reporting that 41% of adolescents perceived prescription drugs to be safer
than illegal drugs and almost a third (29%) believed that prescription pain relievers were
not addictive (Martin et al., 2014). Finally, exposure to opioids as an adolescent appears
to present a risk for problematic opioid use as an adult. A longitudinal study, using data
from the Centers for Disease Control (CDC) Monitoring the Future study (The Regents
of the University of Michigan, 2016), found a significant association between both
medical and nonmedical use of prescription opioids during adolescence and subsequent
non-medical use of opioids when participants were 35 years of age (McCabe, Veliz, &
Schulenberg, 2016). Additional work in this area found that adolescents who selfreported medical and nonmedical opioid use were more likely to engage in medical use
before nonmedical use (McCabe et al., 2017). In other words, any exposure to opioids
(e.g. medical or non-medical) during adolescence may carry with it potential for short
and long-term risk.
Individual Factors Associated with Receiving an Opioid Prescription Before Age 21
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Two other key areas lack clarity in relation to patterns of pediatric opioid
prescribing. First is identification of what individual factors are associated with receipt of
an opioid prescription as a young person. Some available data suggests that ethnic
minority youth are less likely to receive an opioid for pain (Groenewald et al., 2015;
Pletcher, Kertesz, Kohn, & Gonzales, 2008; Sadhasivam et al., 2012; Wu, Woody, Yang,
Pan, & Blazer, 2011), despite reporting pain of greater intensities than Caucasian youth
(Pletcher et al., 2008; Sadhasivam et al., 2012; Wu et al., 2011). Other data indicates that
youth who are older (Groenewald et al., 2015), have a preexisting mental health diagnosis
(Richardson et al., 2012; Welsh et al., 2017), or multiple pain complaints (Richardson et
al., 2011) are more likely to receive an opioid or misuse opioids. Overall, the influence of
other potentially important demographic and health-related variables requires further
examination. It is also perplexing that although the prevalence of chronic pain is higher in
female youth (King et al., 2011), research has not found significant differences in opioid
prescribing rates to youth based on sex. In terms of misuse, however, one recent study
with a non-clinical population did find that more males than females reported nonmedical opioid use (Osborne, Serdarevic, Crooke, Striley, & Cottler, 2017) and national
rates of drug overdose death rates for males age 15-19 were higher than that of females
(Curtain et al., 2017).
Additionally, to our knowledge, there are no data available investigating how
aspects of opioid dose or prescription frequency may influence health-related outcomes
in youth. Specifically, there is a need to examine demographic and health-related factors
in relation to the number of opioid prescriptions received (i.e., single versus multiple) and
whether number of opioid prescriptions is associated with more problematic outcomes.
This knowledge gap is significant because it is documented that opioid dependence and
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withdrawal symptoms can be identified in children prescribed opioids after as little as
seven days (Galinkin & Koh, 2014). Further, chronic opioid use (receipt of 3 or more
prescriptions [Chou, Fanciullo, Fine, Adler, et al., 2009; Chou, Fanciullo, Fine,
Miaskowski, et al., 2009; Portenoy, 1996]) in adults is associated with greater distress
and disability, more frequent opioid misuse, and may be a risk factor in progression to
heroin use (Chou, Fanciullo, Fine, Adler, et al., 2009; Dowell, Haegerich, & Chou, 2016;
Højsted, Nielsen, Guldstrand, Frich, & Sjøgren, 2010; Kobus et al., 2012; Mars,
Bourgois, Karandinos, Montero, & Ciccarone, 2014).
Opioid Prescribing in a High-risk, Diverse state
Opioid prescribing rates and overdose death rates vary significantly between
states (Center for Disease Control, 2016; Centers for Disease Control and Prevention,
2014). The State of New Mexico (NM) consistently has one of the highest rates of druginduced deaths, with 24.7 deaths per 100,000 people in 2015, 82% of which involved
prescription opioids or heroin (New Mexico Department of Health, 2017). In NM youth,
who comprise over one quarter of the state population (United States Census Bureau,
2016), prescription opioids are the second most commonly used drug behind marijuana,
with prevalence highest among males and those who identify as American Indian
(Substance Abuse Epidemiology Section New Mexico Department of Health, 2016).
From 2000 to 2014, overdose deaths in NM youth aged 0 to 24 years, largely from
opioids, accounted for 8.5% of all overdose deaths in the state (Substance Abuse
Epidemiology Section New Mexico Department of Health, 2016). In Albuquerque, the
state’s largest city, a recent city-wide needs assessment of changes in opioid use and
treatment availability reflected an increase in both nonmedical opioid use and in youth
seeking treatment for problematic opioid use (Greenfield, Owens, & Ley, 2014).
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Treatment agencies interviewed for this needs assessment shared clinical observations
that youth, particularly those with chronic pain, are initiating use with prescriptions
opioids and eventually switching to heroin to save money.
Opioid Prescribing Practices in Pediatrics
In 2015, the U.S. Food and Drug Association (FDA) approved the use of an
opioid, OxyContin, for non-cancer pain treatment in pediatric patients age 11 to 16 years
(U.S. Food and Drug Administration, 2015). Several sets of published guidelines exist for
administration of opioids for chronic non-cancer pain treatment in adults (American
Academy of Pain Medicine, American Pain Society, & American Society of Addiction
Medicine, 2004; Chou, Fanciullo, Fine, Adler, et al., 2009; Costello, 2015; Dowell et al.,
2016), but there is a dearth of clear guidelines specifically for using opioids with youth.
Delineating opioid prescription patterns in youth from preexisting data can illuminate
areas of inconsistency, inequality, or inappropriate prescribing that may be useful in the
development of pediatric opioid prescription guidelines which incorporate the dual goals
of improving patient outcomes and minimizing risks of adverse consequences.
The Current Study
For the current study, data were extracted from the University of New Mexico
Hospital (UNMH) medical records system for all youth age 21 and under who received at
least one outpatient opioid prescription between January 2005 and December 2016. The
primary aim was to quantify trends in prescription of opioids to youth from 2005 to 2016
in NM based on year, demographic, and medical variables. The secondary aims were to:
1) identify individual factors associated with receipt of single or multiple prescriptions,
and 2) examine outcomes following last opioid prescription, including markers of
morbidity (e.g. receipt of a prescription for medication-assisted treatment) and mortality,
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as well as identification of individual and medication characteristics associated with
increased risk of experiencing an adverse outcome.
It was hypothesized that rate of opioid prescriptions to youth in NM would
significantly increase from 2005 to 2016, and that differences in prescribing rates would
be observed based on demographic (e.g. sex, ethnicity) and clinical (e.g. diagnosis)
characteristics, consistent with the published literature. Regarding Aim 2, it was further
hypothesized that only a small proportion of youth would receive more than one opioid
prescription and that, consistent with the extant literature regarding differences in
prescribing rates based on ethnicity, non-Hispanic Whites would be more likely to
receive multiple opioid prescriptions in comparison to members of racial/ ethnic minority
groups (Groenewald et al., 2015). Finally, based on trends in the adult literature (Hooten,
St Sauver, McGree, Jacobson, & Warner, 2015), it was hypothesized that receipt of
repeat or multiple prescriptions would be associated with increased rates of morbidity and
mortality relative to single prescriptions.
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Chapter 2
Methodology
Setting and Data Source
Pre-existing data was extracted from the electronic medical records system at the
University of New Mexico Hospital (UNMH). The hospital is located in an urban area,
serves as New Mexico’s only Level 1 trauma center, and is the primary site of pediatric
specialty care. Data were extracted and de-identified using the services of the UNMH’s
Clinical Translational Science Center (CTSC). The CTSC team acts as an “honest
broker” to evaluate patients in relation to stated inclusion criteria, extract the requested
variables from the electronic health record (EHR), and de-identify patient health
information (PHI) to safeguard confidentiality. The UNMH EHR was established in
2005, thus, data extraction dates were from January 1, 2005 to December 31, 2016.
Institutional Review Board approval was obtained to perform the data extraction
and planned analyses detailed below. The study was deemed “Exempt” as data were preexisting and de-identified (Study approval ID: 16-123).
Measures
Inclusion criteria along with extracted variables in the dataset are presented in
Table 1 and summarized below. Only encounters with opioid prescription dates within
the study time frame were extracted and included.
Sample included patients age 0 to 21 years who received an outpatient
prescription for an opioid between 2005 and 2016. Inpatient opioid prescriptions were
excluded.
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Individual/ baseline demographic factors include relevant descriptive medical
and psychosocial characteristics. These included age at first prescription encounter, race,
ethnicity, and insurance payer status.
Opioid prescription variables were extracted for each outpatient visit where
an opioid was prescribed in order to characterize aspects of the prescription and
encounter (e.g. encounter location, active diagnoses). Type of opioid prescription was
classified based on the active opioid agonist agent (e.g. oxycodone and
acetaminophen/oxycodone were both classified as “oxycodone”): Oxycodone,
Hydrocodone, Codeine, Tramadol, Morphine, Fentanyl, and Other (i.e. meperidine,
opium products). Prescriptions for opioid antagonists (e.g., Methadone, Suboxone) were
excluded, as they can be used for pain management or medication-assisted treatment of
an opioid use disorder and medication indication was not always inferable from the data.
A total of 99 individuals in the dataset received prescriptions for both an opioid agonist
and an antagonist.
The total number of opioid prescriptions received by each individual during each
year of the data extraction period and over the course of the study timeframe was tallied
to derive the total number of prescriptions. Furthermore, a binary variable was created to
denote if individuals received single or multiple opioid prescriptions over the study
period.
Outcomes variables were defined as markers of morbidity (overdose, receipt of a
prescription for medication-assisted treatment) and mortality.

Variable Extraction and Coding Methodology
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Each case was assigned a unique ID number (in order to link patients across
multiple encounters) and each prescription encounter was also assigned a unique ID by
the CTSC. Frequency of opioid prescriptions across the study time frame was calculated
for each patient into a “total opioid prescriptions” variable. A binary variable denoting
individuals who received single versus multiple opioid prescriptions was also created.
Patient age at first opioid prescription was calculated in years. Age at baseline was
categorized into early childhood (0-5 years), school age (6-11 years), adolescent (12-17
years), and young adult (18-21 years). Encounter location was coded as outpatient,
emergency, discharge from inpatient, or day surgery. Insurance payer status was coded
into three categories: Private/ Commercial, Public/ Government Assistance (e.g.
Medicaid), and Uninsured.
To examine outcomes following the patient’s most recent opioid prescription
encounter, patients were tracked one year after their last opioid prescription. At each
subsequent encounter, we looked for evidence of a prescription for medication-assisted
treatment (MAT; i.e. suboxone) as a proxy for potential development of opioid
dependency. The overdose and mortality variables were extracted from the patient’s
entire medical history after receipt of an opioid. Additional descriptive variables were
extracted for each overdose encounter, including documented substances at overdose and
total number of overdoses.
Diagnoses from encounters occurring on October 1, 2015 and later utilized ICD10 codes, due to a hospital wide transition; diagnoses from encounters prior to that date
utilized ICD-9 codes. To integrate ICD-9 and ICD-10 diagnoses, coding of ICD-10
chapters and subchapters was based on ICD-9 chapters and subchapters (as the majority
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of cases had ICD-9 diagnosis), such that each ICD-10 diagnosis was grouped into the
related ICD-9 chapter/ subchapter.
Statistical Analysis Plan
Database merging, cleaning, and coding, was conducted using Excel and R (R
Core Team, 2014) and analyses were conducted using SPSS v25 (IBM Corp. Released,
2015). Descriptive statistics and frequencies were calculated for all sociodemographic,
medical, medication, and outcome variables. Frequencies across time were calculated for
opioid prescriptions, individuals receiving single versus multiple prescriptions, and
markers of opioid-related morbidity and mortality. Relative risk, including 95%
confidence intervals, was calculated for receipt of single versus multiple prescriptions, as
well as markers of morbidity and mortality based on individual sociodemographic
characteristics
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Chapter 3
Results
From 2005-2016, 42,020 unique patients age 21 or younger received a total of
71,647 opioid prescriptions. Table 2 provides an overview of annual frequency of opioid
prescriptions as well as number of patients receiving single or multiple opioid
prescriptions.
Medication and Demographic Characteristics at Receipt of First Opioid (baseline)
Medication Characteristics. The highest number of individuals received their
first opioid prescription in 2008 (n=4,439), in contrast to 2005 when only 1,733 youth
received an opioid prescription for the first time (see Table 3). Type of first opioid
prescription was most commonly Oxycodone (46.0%, n=19,318) or Hydrocodone
(36.5%, n=15,331), while few (<.1%, n=16) received Fentanyl as a first opioid
prescription. We were unable to calculate Morphine Equivalent Dose (MED) for each
prescription, as only a very small percentage of prescriptions (<20%) had adequate
dosing information to calculate MED.
Demographic characteristics. See Table 3 for demographic characteristics of
patients. Mean age at receipt of first opioid prescription was 13.52 (sd = 6.50), although
38.9% (n=16,327) of patients were young adults (age 18-21 years) at the time of their
first prescription. The sample was primarily male (55.0%, n=23,093), of Hispanic/Latino
ethnicity (50.1%, n=21,044), and most commonly reported races were White (48.3%,
n=19,985) and American Indian/Alaskan Native (11.0%, 4,553), although 27.1%
(n=11,241) of the sample declined to report their race or it was missing from the medical
record. Patient primary language was English for most (88.9%, n=37,343), followed by
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Spanish (8.9%, n=3,755). Half of the sample had public or government assisted health
insurance (e.g., Medicaid; 50.1%, n=21,027).
Encounter location. Location of first prescription encounter was most commonly
in the emergency department (35.6%, n=14,954) or at discharge from inpatient care
(29.4%, n=12,364). Opioid prescriptions were least likely to be prescribed in an
outpatient clinic encounter (12.9%, n=5,401).
Total opioid prescriptions. The majority of youth (68.80%, n=28,911) received
only one opioid prescription during the study time frame, while 13,109 (31.20%)
received two or more opioid prescriptions (see Table 3). Of the patients who received
multiple prescriptions, most received two (56.91%, n=7,460), but a marked 22.2%
(n=2,915) received 4 or more opioid prescriptions.
Non-opioid medications. Regarding other potentially interacting prescription
drugs that were prescribed concurrently with the first opioid prescription,
Benzodiazepines and Muscle Relaxants were most common, with 3.5% of the sample (n=
1465) who had an active prescription for Benzodiazepines, 1.5% prescribed Muscle
Relaxants (n=618), and 0.4% prescribed an SSRI or SNRI (n=163). Individuals were
rarely also prescribed anticonvulsants, tricyclic anti-depressants, or barbiturates (< .1%).
Presenting diagnoses. On average patients had 5.06 (sd = 5.41; range 1-64)
presenting diagnoses tied to the encounter where the first opioid prescription was given;
thus, baseline diagnoses are not mutually exclusive (see Table 4). Diagnoses were most
frequently from the ICD-9 chapters for “Injury and Poisoning” (most common diagnoses
in this chapter were ‘fractures’) and “Supplementary Classification Of External Causes
Of Injury And Poisoning’” chapters (most common diagnosis was ‘vehicle related
injuries’). More broadly, two thirds of diagnoses (67.8%) were coded as acute
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conditions, 10.3% represented a chronic pain related condition (non-cancer), 2.6% were
cancer related, 1.5% were for a mental health condition, and 10.3% indicated the
presence of another non-pain related medical condition (e.g., metabolic disorders).
Medication Characteristics and Prescribing Trends over Time
From 2005 to 2016, overall frequency of opioid prescriptions increased by
86.64% (from 2470 to 4620) with the largest increase (206.15%) observed from 2005 to
2008 (2470 to 7562; see Figure 1 and Table 2). Prescribing rates trended downward
from 2008 to 2016, decreasing by 39.04%.
Number of patients receiving opioids per year increased by 95.10% across the
study time frame (from 1736 patients in 2005 to 3387 patients in 2016; Figure 1 or Table
2), with the largest increase (198.16%) occurring from 2005 to 2008, followed by a
steady decrease in overall sample size through 2016 (-34.56%), mimicking trends in
overall prescription frequency.
The raw number of patients receiving multiple prescriptions within a year
increased from 391 in 2005 to 689 in 2016, but proportionally only increased from
22.53% of the total sample in 2005 to a peak of 24.96% in 2008, followed by a decrease
to 20.34% in 2016 (see Table 2). Thus, the highest number of patients received multiple
prescriptions in 2008 (n=1292) and 2009 (n=1277).
Opioid type. Regarding drug type, Oxycodone was consistently the most
commonly prescribed opioid (e.g., OxyContin, Percocet; see Table 4). Overall rates of
Oxycodone prescribing increased by 135.32% from 2005 (n=1192) to 2016 (n=2805),
peaking in 2010 (n=3389). Tramadol prescriptions increased the most, marked by a
487.5% increase across study time points (from n=16 to 94), including a 600% increase
from 2005 to 2013 (from n=16 to 112). Prescription rates for Fentanyl also decreased by
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50.0% across the study time points, but only after increasing by 140% from 2005 (n=10)
to 2012 (n=24).
Non-opioid medications. In 2016, almost twice as many individuals receiving
their first opioid prescription also had an active prescription for a Benzodiazepine
compared to 2005 (n=81 in 2005 and n=159 in 2016; 96.30% increase). Rates of other
non-opioid medications remained stable over time.
Receipt of Single versus Multiple Prescriptions
Relative risk of receiving multiple versus single opioid prescriptions significantly
increased with age and when morphine or fentanyl was the first opioid prescription type
(see Table 3). In particular, adolescents were 1.66 times more likely to receive multiple
opioid prescriptions than children age 0-5 years (95% CI= 1.58-1.52). White, Englishspeaking, not Hispanic/ Latino patients were also more likely to receive multiple opioid
prescriptions.
Opioid-related Adverse Outcomes
A summary of the frequency of adverse events is in Table 6 and illustrated in
Figure 2. Broadly, large increases were observed in the frequency of adverse events from
2005 to 2016: 2200% increases in incidents of mortality, 1400% increases in patients
receiving medication-assisted treatment, and 1433% increases in overdose incidents.
Over half of patients with documented adverse outcomes received multiple opioid
prescriptions (51.76% of patients who experienced an overdose, 59.73% of patients
receiving MAT, and 57.71% of patients who died), which is a higher percentage of
patients receiving multiple opioid prescriptions than observed in the total sample
(31.20%).
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Overdose. A total of 189 overdose incidents were reported for 170 individuals
(see Tables 6 and 7), as indicated by overdose diagnoses, inpatient admission for
treatment of overdose related symptoms, and/or administration of Naloxone.
Proportionally, 0.45% of the entire sample experienced an overdose during 2005 to 2016,
with the largest annual proportion of patients impacted in 2016 (1.36%) following a
119.05% increase in overdose incidents from 2015 (n=21) to 2016 (n=46). A total of 149
patients (87.60%; see Table 7) experienced 1 overdose, while 21 had two or more
documented overdoses (12.49%). The majority of overdose incidents (98.40%; n=186)
had documented involvement of an opioid (including both prescription opioids and
heroin) in the encounter diagnoses, while 26.50% (n=50) had documentation of
prescription opioids specifically. A total of 32 overdose incidents (16.93%) included
documentation of active suicidal ideation or suicidal attempt via intentional overdose; SI
was most commonly documented in overdose incidents occurring in 2006 (n=10).
Medication-Assisted Treatment (MAT). The percentage of the entire sample
who received a medication for the treatment of opioid dependence (e.g., buprenorphine,
naltrexone, methadone, and buprenorphine-naloxone [Suboxone]) within 1 year of receipt
of an opioid prescription increased from .06% in 2006 (n=1 out of 1736) to .44% in 2016
(n=15 out of 3387), although was highest in 2014 (.58%; n=23 out of 3983).
Mortality. Data was extracted on all incidents of mortality for subjects in the
study sample, not deaths only related to opioid use. Documented incidence of mortality in
individuals prescribed an opioid increased from 2 individuals in 2005 to 46 in 2016 (from
.12% of the sample to 1.39%), impacting a total of 201 patients. Similar to overdose
incident rates, mortality incidents increased most significantly from 2015 (n=23) to 2016
(n=46; an increase of 100%). Cause of mortality was unknown for most patients. On
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average, deaths occurred 3.40 years (sd= 3.24; range 0-13 years) after receipt of the first
opioid prescription.
Differences in Outcomes Based on Medication and Individual Characteristics
Table 8 includes a summary of medication-related and demographic
characteristics of patients with documented markers of morbidity and mortality following
receipt of an opioid prescription as well as relative risk of experiencing adverse outcomes
based on these characteristics. Overall, increased risk for adverse outcomes differed
significantly based on type of first opioid prescription, older age, minority status
(specifically for mortality), encounter type, payer status, and receipt of multiple
prescriptions.
Medication characteristics.
Year of first opioid. Patients who died or received MAT most commonly received
their first opioid prescription in 2012 or earlier. Patients who experienced an overdose
most commonly received their first opioid prescription from 2006- 2009, consistent with
overall prescribing trends.
Type of first opioid prescription. Patients who experienced an overdose or
received MAT were most commonly prescribed Oxycodone. Receipt of Morphine was
associated with a 22.40-fold (95 CI=13.5-37.15) increased risk of receiving MAT and a
64.39-fold increased risk of death (95% CI= 44.91-92.34) than Oxycodone. Similarly, the
risk of receiving MAT or of mortality after receipt of a Tramadol prescription was 3.32
times (95% CI= 1.23-8.96) and 32.63 times (95% CI= 8.75-121.69) greater than
Oxycodone.
Encounter type. Patients receiving MAT and patients who died most commonly
received their first opioid prescription during discharge from an inpatient admission
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(39.60%, n=59; 42.20%, n=85, respectively). In relation to the total sample, 1.20% of the
sample (n=65) who received an opioid prescription during an outpatient encounter died.
Subsequently, relative risk for adverse outcomes was significantly reduced when
receiving the first opioid prescription during an emergency, inpatient discharge, or day
surgery encounter in comparison to outpatient encounters.
Frequency of opioid prescription. A larger proportion of patients receiving
multiple opioid prescriptions experienced adverse outcomes as compared to patients who
received only one opioid prescription. Most notably, of all patients who received 4 or
more opioid prescriptions, 1.20% experienced an overdose (n=35), 1.48% received MAT
(n=43), and 2.16% died (n=63). For comparison, 0.21-0.29% of all patients who received
a single opioid prescription experienced an adverse outcome. Relative risk of adverse
outcomes for individuals receiving multiple opioid prescriptions versus single
prescriptions steadily increased as number of prescriptions increased. In particular, in
patients who received 4 or more opioid prescriptions, the risk of overdose was 4.23 times
greater (95% CI= 2.86-6.28), the risk of receiving MAT was 7.11 times greater (95% CI=
4.81-10.50), and the risk of mortality was 7.35 times greater (95% CI=5.32-10.16).
Individual characteristics.
Age at first opioid prescription. The majority of patients who experienced an
overdose (94.12%, n=160) or received MAT (87.24%, n=130) received their first opioid
prescription during adolescence (age 12-17 years) or as a young adult (age 18-21 years).
Subsequently, adolescents and young adults were at increased risk of adverse events
relative to youth age 11 and under, particularly overdose (RR=8.18, 95% CI= 4.32-15.49)
and MAT (RR=3.50, 95% CI= 2.16-5.66). Age at first opioid prescription in patients who
died was more varied: 32.34% (n=65) of deceased patients received their first opioid
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prescription during adolescence, while 28.86% were age 0-5 years are receipt of first
opioid (n=58).
Sex. Males were 1.35 times more likely to die (95% CI- 1.01-1.79) in comparison
to females. Proportionally, more females than males received MAT (58.39%, n=87).
Ethnicity, Race, and Primary Language. Proportionally, within the entire
sample, more racial minority patients died than white patients. Specifically, 4.34%
(n=18) of all Asian patients, 2.17% of all Black/ Africa American patients, and 1.45% of
American Indian/ Alaska Native patients died in comparison to 0.43% of all White
patients; however, frequency of death was highest among White patients (42.29%, n=85)
followed by American Indian/ Alaskan Native patients (32.84%, n=66). Additionally,
relative risk of death was significantly greater in minority patients in comparison to
White patients (3.41-10.20x greater). Equal proportions of the entire sample of
Hispanic/Latino and Not Hispanic/Latino identifying patients died (.45% and .46%,
respectively), although a greater frequency of deaths occurred in Hispanic/Latino patients
(n=96, 46.27%, vs. n=53, 26.37%, of Non-Hispanic/Latino patients).
Overdose occurred most often in Hispanic/Latino (n=95, 55.89%, 0.45% of the
total sample) and White patients (n=101, 59.42% of overdoses; 0.51% of the total
sample. Similarly, Hispanic/Latino patients (n=90, 60.40%, 0.43% of the total sample)
and White patients (n=91, 61.07%, 0.46% of the total sample) were more likely to receive
MAT. Proportionally, within the entire sample, a marked 6.27% (n=26) of Asian patients
received MAT and these patients were at 13.27 times higher risk (95% CI= 9.00-21.04)
of receiving MAT compared to White patients. Primary language was English for nearly
all patients experiencing adverse outcomes (87.56%- 96.79%), consistent with the full
sample.
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Payer Status. Public/government assistance (e.g., Medicaid) was the most
common type of insurance for patients experiencing all three outcomes (42.78%60.70%). Patients who were uninsured were 2.93 times more likely to experience an
overdose (95% CI= 1.96-4.39) and 2.42 more likely to receive MAT (95% CI= 1.474.01) when compared to privately insured patients.
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Chapter 4
Discussion
The current study utilized pre-existing data drawn from the medical records
system of a large university hospital to evaluate opioid prescription rates to youth in New
Mexico (NM), as rates of prescription of opioids to children and adolescents at a
statewide level were unknown. Further, individual factors and outcomes associated with
receipt of single or repeat prescriptions and adverse outcomes were characterized to
increase understanding of the prevalence and impact of opioid prescriptions. This large
and comprehensive dataset captured several important variables, which allowed for
examination of relations amongst hypothesized risk factors and opioid-related outcomes
following the last opioid prescription. Unique aspects of this study are the racial and
ethnic diversity of the sample, geographic location (rural, high-risk state for opioid
use), utilization of hospital medical records data (rather than insurance claims data
or data gathered via patient self-report), consideration of individual factors
associated with receipt of multiple opioid prescriptions, and preliminary evaluation
of longitudinal outcomes following receipt of an opioid prescription.
Overall, substantial increases in prescription of opioids to youth in New Mexico
as well as rates of opioid-related morbidity and mortality were observed. Despite
downward trends in prescribing rates from 2008 to 2016, increases in opioid-related
morbidity and mortality persisted. Patients who were older, White, not Hispanic/ Latino,
and English-speaking were more likely to receive multiple opioid prescriptions, which is
consistent with previous literature related to individual factors associated with receipt of
any opioid (Groenewald et al., 2015; Pletcher et al., 2008; Sadhasivam et al., 2012; Wu et
al., 2011), but not necessarily multiple opioids, as we are not aware of any preexisting
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data in that domain. Increased risk of adverse outcomes was observed in patients
receiving more than one opioid prescription, as well as patients who were older, of a
minority racial background, publicly insured or uninsured, and who received Tramadol,
Fentanyl, or Morphine as a first opioid prescription. Limitations of the current dataset did
not allow for examination of some previously identified risk factors for opioid misuse in
youth, including the presence of chronic pain, exposure to trauma, and other substance
use (Groenewald, Law, Fisher, Beals-Erickson, & Palermo, 2019). A unique finding in
this sample is that Asian patients, who comprised a small subset of the sample (1.0%) and
represent a small subset of the overall population in New Mexico, had significantly
proportionally higher rates of adverse events including much higher risk for receiving
medication-assisted treatment (MAT) and death.
Results from the present study suggest that prescription of opioids to youth in
New Mexico is occurring with greater frequency in comparison to national prescribing
trends, such as those reported by Groenewald et al. (2015). Interestingly, Groenewald et
al. (2015) found that overall prescribing rates to youth in the United States remained
stable and low, but significant increases in youth receiving 5 or more opioid prescriptions
were observed. In contrast, rates of youth receiving multiple opioids in this dataset did
not increase substantially over time. Thus, prescribing trends to youth in New Mexico
appear more similar to adult prescribing trends in the US (Manchikanti et al., 2010;
Shaheed et al., 2016; Vowles et al., 2015), particularly when examined in relation to the
high rates of opioid-related morbidity and mortality. In line with national findings in
adults, decreases in opioid prescribing within this sample did not equate to decreases in
opioid-related morbidity and mortality (Centers for Disease Control and Prevention
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National Center for Health Statistics, 2015; Jones et al., 2013; Rudd et al., 2016; Vowles
et al., 2015).
Although not explicitly captured in this dataset, there are several identified “risk
factors” (Groenewald et al., 2019) for opioid misuse that are common among youth in
New Mexico that likely make them more vulnerable to adverse outcomes and may
explain differences in state versus national rates. Specifically, New Mexico consistently
ranks as among the worst states for high rates of childhood trauma (a risk factor which
has been linked to opioid use in adulthood (Groenewald et al., 2019)), including
substance use in utero and high rates of infants born drug-dependent, as well as
adolescent substance use (Gallagher et al., 2018). Geographically New Mexico is
primarily rural and demographically, ethnically diverse. Previous work has identified
adolescents living in rural areas as being at 35% greater odds of engaging in prescription
opioid misuse (Monnat & Rigg, 2015) and high opioid prescribing rates have been
recorded geographically in the southern United States (Rolheiser, Cordes, &
Subramanian, 2018), but not NM in particular. Additionally, unmanaged pain has been
repeatedly identified as a primary motive for nonmedical opioid use in adolescents (e.g.
McCabe, West, & Boyd, 2013b). One potential driver of opioid prescribing and misuse
rates in a rural state such as New Mexico could be difficulty accessing nonpharmacological evidence-based pain management resources, due to geographic location
and/or lack of availability of these resources. At this time, New Mexico does not have a
specialized interdisciplinary pediatric pain rehabilitation program (American Pain
Society, 2015), the gold standard of treatment for disabling chronic pain (Hechler et al.,
2015). Additionally, given that over a third of youth in New Mexico grow up in poverty,
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several barriers may be present to traveling out of state for specialized treatment
(Gallagher et al., 2018).
While cause of death for patients in the sample is unknown, the large increase in
mortality within the sample is perplexing and worrisome. Death rates in children and
adolescents within the state have not increased, although, drug overdose deaths in New
Mexico have risen since 2001 (Gallagher et al., 2018). Consistent with the present
sample, American Indian youth in New Mexico die at more than twice the rate of other
racial groups. Nationally, rates of adolescents dying from opioid-related complications
are increasing, with a notable increase from 2014-2015 (Curtain et al., 2017). A notable
subset of early childhood aged children died (age 0-5 years; n=58, .78% of the total
sample of that age group). Since cause of death was unknown, it is hard to know if this
may be related to accidental injury/ overdose of opioids or perhaps greater disease
severity (e.g. cancer). Similarly, Fentanyl use with children is fairly rare, except during
palliative care; thus it is recommended that the finding that youth prescribed Fentanyl
were more likely to die should be interpreted with caution and within this clinical
context, rather than in relation to rising Fentanyl-related death rates in the US.
Increases in youth receiving medication-assisted treatment (MAT) for an opioid
use disorder is a finding that comes with mixed implications. It is hard to know if this is
reflective of an increase in incidence of opioid use disorders (OUD) or an increase in
patients accessing treatment for an OUD; it is also unclear if MAT is being administered
for prescription opioid dependency or heroin dependency. Increases in adolescents and
young adults seeking MAT for an opioid use disorder further highlights previous findings
(Greenfield et al., 2014) regarding the need to increase access to developmentally
appropriate behavioral based treatments in conjunction with MAT in New Mexico. It is
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well documented that patient abstinence and adherence rates while receiving MAT
remain sub-optimal (Krupitsky et al., 2011; Ling et al., 2010; Mattick, Breen, Kimber, &
Davoli, 2009; Resnick et al., 1992). For adolescents and young adults, in particular,
developmentally appropriate behavioral treatments combined with MAT are
recommended (COMMITTEE ON SUBSTANCE USE AND PREVENTION, 2016).
Finally, results in the current study underscore previously documented relations
between non-medical prescription opioid use and suicidal ideation (Divin & Zullig,
2014), suggesting a need for interventions that address co-morbid mental health needs in
concert with pain treatment. This finding also underscores the importance of safe storage
and disposal of leftover opioids, as increased access to means for suicide increases risk of
attempt and completion. Future research should carefully monitor suicidal ideation in
youth prescribed an opioid to determine if the patient is at significant risk for intentional
overdose. Relatedly, this work highlights the need for careful screening of identified
factors associated with increased risk of adverse outcomes and risky use to inform opioid
prescribing and prescription monitoring practices (e.g. CRAFFT [Knight, Sherritt, Shrier,
Harris, & Chang, 2002; McCabe et al., 2012]). Additional measure development is
needed in this area, however, to ensure that measures are valid and reliable in diverse
populations and do not inappropriately restrict patients from adequate pain management.
Limitations
A feasible way to understand the evolution of opioid prescribing to youth and
identify relevant individual characteristics is to examine existing data. A limitation of this
approach is that data were not collected prospectively, nor was the database designed
specifically to accomplish the study aims. Instead these data come from a clinical
database which did not capture all variables of interest. The “real world” nature of these
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data means that they still contain many relevant variables, and the retrospective aspect
lends itself to immediate availability, perhaps offsetting this limitation. Further, the
hospital data archives can only extract data from 2005 onwards, when the electronic
medical record was implemented, naturally limiting the study timeframe. Thus, study
aims could not be evaluated prior to that date. There is also no way to confirm whether or
not opioid prescriptions were filled, if patients sought additional prescriptions from
providers outside of the university hospital system, or if the first opioid prescription
received during the study timeframe was truly the patient’s first exposure to being
prescribed an opioid (e.g. patients may have received an opioid prescription before 2005).
Frequency of adverse outcomes are also limited to those treated within the UNMH
hospital system. Further, adverse events cannot be causally linked to receipt of an opioid
prescription, however it is known that they occurred temporally after receipt of an opioid
prescription. This dataset also likely only captures a subset of American Indian/ Alaska
Native youth in New Mexico, as many AI/AN families in New Mexico receive care
through Indian Health Services. Additionally, due to deidentification procedures,
prescriptions dates could only be provided in years, rather than month and year and
prescription start/ stop dates were not available; thus it was not possible to accurately
calculate length of time between prescriptions. Finally, while it was intended to calculate
Morphine Equivalent Dose (MED) to look at changes in dosing over time and
associations with different baseline characteristics (e.g. race/ ethnicity), less than 20% of
prescriptions had adequate data (e.g. dose and frequency) to calculate MED. Thus, we
were unable to perform those analyses. It is also a limitation that a subset of patients
declined to report or had missing values for race (27.1%) and/or ethnicity (22.5%).
Conclusions and Significance
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As life expectancy in the United States has declined for two years in a row,
attributable largely to the increase in opioid overdose mortality among young adults and
adults (Kochanek et al., 2017), the importance of quantifying opioid prescription rates to
youth, a key access point for nonmedical use, and associated adverse outcomes cannot be
overstated. This is the first epidemiological study using hospital level data to examine
opioid prescribing rates and associated longitudinal outcomes to children and adolescents
in a high-risk state. Much of the available research on opioid prescribing rates to youth
has been primarily derived from insurance claim databases (e.g. Groenewald et al., 2015;
Richardson et al., 2011), rather than medical records data, limiting the clinical utility and
generalizability of findings. Contributions from this research address several gaps in our
understanding of opioid prescribing trends to children and adolescents including: 1)
comprehensive quantitative measurement of prescribing rates of opioids to youth in New
Mexico, 2) identification of individual factors in multiple domains associated with receipt
of multiple opioid prescriptions and adverse outcomes 3) examination of prevalence of
longitudinal outcomes (e.g. morbidity and mortality) after receipt of an opioid
prescription.
In particular, this study contributes to the growing literature base identifying
factors associated with receipt of opioid prescriptions in youth and risk factors predictive
of less favorable outcomes, including overdose and death. A new finding from this
dataset is that, consistent with adult literature, receipt of more than one opioid
prescription was associated with greater risk for opioid-related adverse consequences,
highlighting potential additive risks of adverse outcomes when pediatric patients receive
single versus multiple opioid prescriptions. This finding needs to be replicated in other
samples of youth. Finally, the large difference in trends of opioid prescribing rates to
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youth in New Mexico versus nationally indicates that national statistics may not be
accurately representative of all states. In order to effectively and appropriately distribute
intervention and treatment resources to the highest need areas, trends may need to be
evaluated locally.
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Figure 1.
Opioid prescribing trends over time in individuals who received single or multiple opioid prescriptions
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Figure 2.
Trends in adverse events in patients who received at least one opioid prescription
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Table 1.
Variables extracted from patient electronic medical records
Inclusion criteria: Age 0-21, Prescribed an opioid during an outpatient encounter (e.g. Emergency Department,
discharge from an inpatient admission, day surgery, or outpatient clinic)
Exclusion criteria: Inpatient opioid prescription encounters
Variables of interest
Individual/ baseline
Opioid prescription encounter
Adverse outcomes
Data extracted once for each
Data extracted from each encounter Data extracted from each clinical
patient
where an opioid was prescribed
encounter for 12 months following first or
last prescription
Age
Medication-related characteristics: Markers of morbidity
Sex
Encounter location
Overdose (admission, ED encounter)
Ethnicity
Name of drug
Medication-Assisted Treatment
Race
Prescribed dose
Death
Primary language
Duration/ dispense value
Subsequent diagnoses
Payer status
Total # of opioid prescriptions
Non-opioid prescriptions
Number of years receiving
Other pain medications
multiple opioid prescriptions
Psychiatric medications
Active diagnoses
Premorbid diagnoses
Note. An “encounter” is defined as a unique clinical instance of direct provider to patient interaction; Payer
status= Public/ Government Assistance (e.g. Medicaid), Private, or Uninsured; Encounter location= Emergency,
discharge from inpatient, outpatient, or day surgery; Diagnoses will also coded as Acute, Chronic pain, Mental
Health, Other Co-Morbid Condition, or Cancer Related; Prescribed dose will be converted to Morphine
Equivalent Dose.
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Table 2.
Annual sample characteristics including total opioid prescriptions and frequency of individuals receiving single vs. multiple
prescriptions
Total patients
Total patients
Patients who
Patients who
% of sample
Total annual
receiving their
who received an
received a
received
receiving
opioid
first opioid
opioid
single opioid
multiple opioid multiple opioid
Year
prescriptions
prescription*
prescription**
prescription
prescriptions
prescriptions
2005
2470
1733
1736
1345
391
22.52%
2006
5150
3431
3644
2830
814
22.34%
2007
7000
4374
4864
3725
1139
23.42%
2008
7562
4439
5176
3884
1292
24.96%
2009
7487
4280
5124
3847
1277
24.92%
2010
7215
4128
4980
3839
1141
22.91%
2011
6974
3940
4846
3704
1142
23.57%
2012
6295
3574
4452
3443
1009
22.66%
2013
6203
3503
4337
3343
994
22.92%
2014
5736
3153
3983
3081
902
22.65%
2015
4945
2777
3470
2658
812
23.40%
2016
4610
2688
3387
2698
689
20.34%
TOTAL
71647
42020
49999
38397
11602
23.20%
*Represents number of unique patient in the dataset.
**This includes more patients than in the first column because some individuals received prescriptions in multiple years.
Thus, each patient is counted only once per year, but may show up in multiple years.
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Table 3.
Medication-related and demographic characteristics at receipt of first opioid of patients who received single vs. multiple prescriptions
Full Sample
Single opioid
Multiple opioid
Relative risk for
N= 42,020
N=28,911
N= 13,109
multiple opioids
N
%
N
%
N
%
(95% CI)
Year of first prescription
2005†
1,733 4.1%
1047
3.6%
686
5.2%
REF
2006
3,431 8.2%
2182
7.5%
1249
9.5%
.92 (.85-.99)
2007
4,374 10.4% 2827
9.8%
1547
11.8%
.89 (.83-.96)
2008
4,439 10.6% 2858
9.9%
1581
12.1%
.90 (.84-.97)
2009
4,280 10.2% 2807
9.7%
1473
11.2%
.87 (.81-.93)
2010
4,128 9.8%
2827
9.8%
1301
9.9%
.80 (.74-.86)
2011
3,940 9.4%
2754
9.5%
1186
9.0%
.76 (.71-.82)
2012
3,574 8.5%
2543
8.8%
1031
7.9%
.73 (.67-.79)
2013
3,503 8.3%
2522
8.7%
981
7.5%
.71 (.65-.77)
2014
3,153 7.5%
2315
8.0%
838
6.4%
.67 (.62-.73)
2015
2,777 6.6%
2044
7.1%
733
5.6%
.67 (.61-.73)
2016
2,688 6.5%
2185
7.6%
503
3.8%
.47 (.43-.52)
Total opioid prescriptions
1
28,911 68.8% 28,911 100%
---2
7,460 17.8%
--7,460
56.9%
-3
2,734 6.5%
--2,734
20.9%
-4 or more
2,915 6.9%
--2,915
22.2%
-First opioid prescription type
Oxycodone†
19,318 46.0% 12547 43.4% 6771
51.6%
REF
Hydrocodone
15,331 36.5% 11120 38.5% 4211
32.1%
.78 (.76-.81)
Codeine
6,907 16.4% 5006 17.3% 1901
14.5%
.79 (.75-.82)
Tramadol
253
0.6%
154
0.5%
99
0.8%
1.12 (.96-1.30)
Morphine
150
0.4%
57
0.2%
93
0.7%
1.77 (1.56-2.01)
Fentanyl
16
<.1%
6
0.02%
10
0.01%
1.78 (1.22-2.61)
Other
45
.1%
21
0.1%
24
0.2%
1.52 (1.16-2.00)
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Full Sample
N= 42,020
N
%
Age
Early childhood (0-5 years) †
School age (6-11 years)
Adolescent (12-17 years)
Young-adult (18-21 years)
Sex
Female †
Male
Ethnicity
Not Hispanic/ Latino†
Hispanic/ Latino
Not reported
Race
White†
American Indian/Alaska Native
Black/African American
Two or More Races
Asian
Hawaiian Native/ Pacific Islander
Other
Decline to answer/ unavailable
Primary language
English†
Spanish
Other/ Not reported
Encounter type
Outpatient†
Emergency
Discharge from inpatient

Multiple opioid
N= 13,109
N
%

Relative risk for
multiple opioids
(95% CI)

20.0%
16.7%
25.0%
38.3%

1652
1961
4231
5265

12.6%
15.0%
32.3%
40.2%

REF
1.30 (1.23-1.37)
1.66 (1.58-1.52)
1.45 (1.38-1.52)

18,927 45.0% 12,974 44.9%
23,093 55.0% 15,937 55.1%

5,953
7,156

45.4%
54.6%

REF
.99 (.96-1.01)

11,496 27.4%
21,044 50.1%
9,480 22.5%

26.3%
49.7%
24.0%

3878
6681
2550

29.6%
51.0%
19.5%

REF
.94 (.91-.97)
--

19,985 48.3% 13,239 46.5%
4553 11.0% 3144 11.0%
1292
3.1%
835
2.9%
539
1.3%
372
1.3%
415
1.0%
313
1.1%
96
0.2%
65
0.2%
3295
8.0%
2579
9.1%
11,241 27.1% 7946 27.9%

6746
1409
457
167
102
31
716
3295

52.2%
10.9%
3.5%
1.3%
0.8%
0.2%
5.5%
25.5%

REF
.92 (.87-.96)
1.05 (.97-1.13)
.92 (.81-1.04)
.73 (.61-.86)
.96 (.72-1.28)
---

37,243 88.9% 25,455 88.3% 11,788
3,755 8.9%
2776
9.6%
979
894
2.1%
588
2.0%
306

90.2%
7.5%
2.3%

REF
.82 (.78-.87)
--

5,401 12.9% 3272 11.3%
14,954 35.6% 11,017 38.1%
12,364 29.4% 7682 26.6%

16.3%
30.0%
35.7%

REF
.67 (.64-.70)
.96 (.92-1.00)

7,432
6,790
11,471
16,327

Single opioid
N=28,911
N
%

17.7% 5780
16.2% 4829
27.3% 7240
38.9% 11,062

7618
14364
6929
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2129
3937
4682

Full Sample
N= 42,020
N
%
9,301 22.1%

Single opioid
N=28,911
N
%
6940 24.0%

Multiple opioid
N= 13,109
N
%
2361
18.0%

Relative risk for
multiple opioids
(95% CI)
.64 (.61-.68)

Day surgery
Payer status
Private/ Commercial†
14,116 33.6% 9619 33.2% 4497
34.2%
REF
Public/ Government assistance
21,027 50.1% 14,304 49.5% 6723
51.3%
1.00 (.97-1.04)
Uninsured
6863 16.3% 4981 17.2% 1882
14.4%
.86( .82-.90)
Non-opioid drugs
Benzodiazepines
1,465 3.5%
718
2.48%
747
5.70%
-Muscle Relaxant
618
1.5%
394
1.36%
224
1.71%
-SSRI/ SNRI
163
0.4%
74
0.26%
89
0.68%
-Anticonvulsants
19
<.1%
10
0.03%
9
0.07%
-Tricyclic anti-depressants
18
<.1%
7
0.02%
11
0.08%
-Barbiturates
8
<.1%
5
0.02%
3
0.02%
-† Patients with this characteristic served as the reference group; CI denotes confidence interval; Bold values indicate
statistically significant values based on the CI. RR for receiving multiple opioids in patients who also received nonopioid drugs was not calculated, as there is not a hypothesis driven rationale for identifying a reference group.
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Table 4.
ICD-9 chapters for presenting diagnoses at encounter for first opioid prescription
(baseline)
ICD-9 Chapter

N

Injury And Poisoning
Supplementary Classification Of External Causes Of Injury And Poisoning
Supplementary Classification Of Factors Influencing Health Status And Contact
With Health Services
Symptoms, Signs, And Ill-Defined Conditions
Diseases Of The Musculoskeletal System And Connective Tissue
Diseases Of The Respiratory System
Diseases Of The Nervous System And Sense Organs
Diseases Of The Genitourinary System
Diseases Of The Digestive System
Complications Of Pregnancy, Childbirth, And The Puerperium
Congenital Anomalies
Diseases Of The Skin And Subcutaneous Tissue
Mental Disorders
Neoplasms
Diseases Of The Circulatory System
Diseases Of The Blood And Blood-Forming Organs
Endocrine, Nutritional And Metabolic Diseases, And Immunity Disorders
Infectious And Parasitic Diseases
Certain Conditions Originating In The Perinatal Period
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34,416
18,142
12,152
10,998
10,224
8333
8205
4690
4320
4012
3662
1966
1899
1869
1713
1360
1252
484
88

Table 5.
Frequency of opioid prescribing over time by type of opioid
Opioid type
Oxycodone
Hydrocodone
Codeine
Morphine
Tramadol
Other
Fentanyl
Yearly Total

2005
1192
675
536
28
16
13
10
2470

2006
2176
1859
999
60
17
16
23
5150

2007
2876
2425
1589
33
43
19
15
7000

2008
3417
2316
1672
42
66
30
19
7562

2009
3609
2238
1441
102
53
26
18
7487

2010
3839
1958
1149
146
67
41
15
7215

2011
3453
2637
611
125
71
56
21
6974

2012
3287
2379
425
64
75
41
24
6295
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2013
3162
2393
367
95
112
54
20
6203

2014
3065
2192
218
106
108
42
5
5736

2015
2958
1744
77
43
96
26
1
4945

2016 TOTAL
2805
35839
1530
24346
81
9165
75
919
94
818
20
384
5
176
4610
71647

Table 6.
Frequency of markers of morbidity and mortality by year in patients who received single vs. multiple opioid prescriptions

Year

Total
patients
who
received an
opioid
prescription

Overdose Incidents

Patients Receiving MedicationAssisted Treatment (MAT)
Single* Multiple* Total
% of
annual
sample*

Single*

Multiple*

Total

% of
annual
sample*

2005

1736

0

0

0

0%

0

1

1

2006

3644

3

0

3

0.08%

2

4

2007

4864

4

3

7

0.14%

0

2008

5176

2

3

5

0.10%

2009

5124

4

8

12

2010

4980

7

3

2011

4846

6

12

2012

4452

7

2013

4337

2014

Mortality Incidents
Single*

Multiple*

Total

% of
annual
sample*

0.06%

2

0

2

0.12%

6

0.16%

2

5

7

0.19%

3

3

0.06%

2

2

4

0.08%

3

7

10

0.19%

5

3

8

0.15%

0.23%

3

8

11

0.21%

5

6

11

0.21%

10

0.20%

6

7

13

0.26%

3

8

11

0.22%

18

0.37%

5

8

13

0.27%

8

13

21

0.43%

12

19

0.43%

13

11

24

0.54%

10

19

29

0.65%

6

10

16

0.37%

10

9

19

0.44%

9

7

16

0.37%

3983

16

16

32

0.80%

12

11

23

0.58%

9

14

23

0.60%

2015

3470

11

10

21

0.61%

4

7

11

0.32%

6

17

23

0.66%

2016

3387

26

20

46

1.36%

2

13

15

0.44%

24

22

46

1.39%

TOTAL

---

92

97

189

0.45%**

60

89

149

0.35%**

85

116

201

0.48%**

*Denotes if the incident occurred in a patient who received single or multiple opioid prescriptions during the study timeframe.
**Percentage of total sample was calculated out of 42,020, number of unique patients in the dataset.
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Table 7.
Characteristics associated with overdose incidents.
Year

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
TOTAL

Unique patients who
experienced an
overdose by year
N=170*
0
3
7
5
11
9
17
19
14
29
19
37
*

Documented substances at overdose
Unspecified opioid
Heroin
Prescription opioids
Prescription opioids & heroin
Other substance

Total overdose
incidents

Documentation of active
suicidal ideation or attempt via
intentional overdose

0
3
7
5
12
10
18
19
16
32
21
46
189

1
10
1
3
4
2
4
1
1
1
2
2
32
(16.93% of incidents)

%
41.30%
30.70%
22.80%
3.70%
1.60%

N
78
58
43
7
3

Total Number of Overdoses
%
N
1
87.60%
149
2
9.40%%
16
3
1.80%%
3
4
1.20%%
2
*Number of unique patients who experienced an overdose =170; since some patients
experienced more than one overdose, they are counted in multiple years.
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Table 8.
Medication and demographic characteristics of patients with markers of morbidity and mortality after an opioid prescription

Year of first opioid
2005†
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Total opioids
Single†
Multiple
2
3
4 or more
First opioid type
Oxycodone†
Hydrocodone
Codeine
Tramadol
Morphine
Fentanyl
Age at first opioid
0-11 years†

Overdose
N= 170
N (% total
Relative Risk
sample)
(95% CI)

Medication-Assisted Treatment
(MAT) N= 149
N (% total
Relative Risk
sample)
(95% CI)

Mortality
N= 201
N (% total
Relative Risk
sample)
(95% CI)

8 (.46%)
29 (.85%)
21 (.48%)
21 (.47%)
23 (.54%)
22 (.53%)
12 (.30%)
10 (.28%)
8 (.23%)
10 (.32%)
2 (.07%)
4 (.15%)

REF
1.83 (.84-4.00)
1.04 (.46-2.34)
1.02 (.45-2.31)
1.16 (.52-2.60)
1.15 (.51-2.69)
0.66 (.27-1.61)
0.61 (.24-1.53)
0.49 (.19-1.32)
0.69 (.27-1.74)
0.16 (.03-.73)
0.32 (.10-1.07)

6 (.35%)
8 (.23%)
11 (.25%)
9 (.20%)
21 (.49%)
19 (.46%)
9 (.23%)
24 (.67%)
15 (.43%)
12 (.38%)
9 (.32%)
6 (.22%)

REF
0.67 (.23-1.94)
0.73 (.27-1.96)
0.59 (.21-1.64)
1.42 (.57-3.51)
1.33 (.53-3.32)
0.66 (.24-1.85)
1.94 (.79-4.74)
1.24 (.48-3.18)
1.10 (.41-2.92)
0.94 (.33-2.63)
0.64 (.21-2.00)

13 (.75%)
26 (.76%)
26 (.59%)
22 (.50%)
15 (.35%)
22 (.53%)
21 (.53%)
21 (.59%)
8 (.23%)
11 (.35%)
9 (.32%)
7 (.26%)

REF
1.01 (.52- 1.96)
0.79 (.41-1.54)
0.66 (.33-1.31)
0.47 (.22-.98)
0.71 (.36-1.41)
0.71 (.36-1.41)
0.78 (.39-1.56)
0.30 (.13-.73)
0.47 (.21-1.04)
0.43 (.19-1.01)
0.35 (.14-.87)

82 (.28%)
88 (.67%)
36 (.48%)
17 (.62%)
35 (1.20%)

REF
2.37(1.75-3.20)
1.70 (1.15-2.52)
2.19 (1.30-3.69)
4.23 (2.86-6.28)

60 (.21%)
89 (.68%)
34 (.46%)
12 (.44%)
43 (1.48%)

REF
3.27 (2.36-4.54)
2.20 (1.44-3.34)
2.11 (1.14-3.93)
7.11 (4.81-10.50)

85 (.29%)
116
27 (36%)
26 (.95%)
63 (2.16%)

REF
3.01 (2.27-3.97)
1.23 (.80-1.90)
3.23 (2.09-5.01)
7.35 (5.32-10.16)

107 (.55%)
47 (.31%)
12 (.17%)
3 (1.19%)
0
0

REF
.55 (.39-.78)
.31 (.17-.57)
2.14 (.68-6.70)
---

92 (.48%)
24 (.16%)
11 (.16%)
4 (1.58%)
16 (10.67%)
0

REF
.33 (.31-.51)
.33 (.18-.62)
3.32 (1.23-8.96)
22.40 (13.5-37.15)
--

74 (.36%)
46 (.30%)
40 (.58%)
1 (.40%)
37 (24.67%)
2 (12.5%)

REF
.78 (.54-1.13)
1.51 (1.03-2.22)
1.03 (.14-7.39)
64.39 (44.91-92.34)
32.63 (8.75-121.69)

10 (.07%)

REF

19 (.13%)

REF

94 (.66%)

REF
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AYA (12-21 years)
0-5 years†
6-11 years
12-17 years
18-21 years
Sex
Female†
Male
Ethnicity
Not Hispanic/ Latino†
Hispanic/ Latino
Not reported
Race
White†
AI/AN
Black/AA
Two or More Races
Asian
Hawaiian/ PI
Other
Decline to answer
Primary language
English†
Spanish
Other/ Not reported
Encounter type
Outpatient†
Emergency
Inpatient discharge

Overdose
N= 170
N (% total
Relative Risk
sample)
(95% CI)
160 (.58%)
8.18 (4.32-15.49)
3 (.04%)
REF
7 (.10%)
2.55 (.66-9.87)
39 (.34%)
8.42 (2.60-27.25)
121 (.74%)
18.36 (5.84-57.71)

Medication-Assisted Treatment
(MAT) N= 149
N (% total
Relative Risk
sample)
(95% CI)
130(.47%)
3.50 (2.16-5.66)
12 (.16%)
REF
7 (.10%)
.62 (.25-1.62)
39 (.34%)
2.11 (1.10-4.01)
91(.56%)
3.52 (1.88-6.26)

Mortality
N= 201
N (% total
Relative Risk
sample)
(95% CI)
107 (.38%)
.58 (.44-.77)
58 (.78%)
REF
36 (.53%)
.68 (.45-1.03)
65 (.57%)
.73 (.51-1.03)
42 (.26%)
.33 (.22-.49)

71 (.38%)
99 (.43%)

REF
1.14 (.84-1.55)

87 (.46%)
62 (.27%)

REF
.58 (.42-.15)

76 (.40%)
125 (.54%)

REF
1.35 (1.01-1.79)

53 (.46%)
95 (.45%)
24 (.25%)

REF
.98 (.70-1.37)
--

40 (.35%)
90 (.43%)
19 (.20%)

REF
1.23 (.85-1.78)
--

53 (.46%)
93 (.45%)
55 (.19%)

REF
.97 (.70-1.36)
--

101 (.51%)
19 (.42%)
15 (1.16%)
0
33 (7.95%)
0
-2

REF
.83 (.51-1.35)
2.30 (1.34-3.94)
-15.73 (10.75-23.0)
----

91 (.46%)
17 (.37%)
12 (.93%)
0
26 (6.27%)
0
0
3 (.03%)

REF
.82 (.49-1.37)
2.04 (1.12-3.71)
-13.7 (9.00-21.04)
----

85 (.43%)
66 (1.45%)
28 (2.17%)
0
18 (4.34%)
0
0
4 (.04%)

REF
3.41 (2.48-4.69)
5.10 (3.34-7.78)
-10.20 (6.19-16.80)
----

165 (.44%)
3 (.08%)
1 (.11%)

REF
.18 (.06-.56)
--

142 (.38%)
0
7 (.78%)

REF
---

176 (.47%)
16 (.43%)
9 (.89%)

REF
.90 (.54-1.50)
--

26 (.48%)
96 (.64%)
31 (.25%)

REF
1.33 (.87-2.05)
.52 (.31-.88)

41 (.76%)
44 (.29%)
59 (.48%)

REF
.39 (.25-.59)
.62 (.42-.93)

65 (1.20%)
31 (.21%)
85 (.69%)

REF
.17 (.11-.26)
.57 (.41-.79)
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Overdose
N= 170
N (% total
Relative Risk
sample)
(95% CI)
13 (.29%)
.29 (.15-.56)

Medication-Assisted Treatment
(MAT) N= 149
N (% total
Relative Risk
sample)
(95% CI)
5 (.05%)
.07 (.03-.18)

Mortality
N= 201
N (% total
Relative Risk
sample)
(95% CI)
20 (.22%)
.18 (.11-.29)

Day surgery
Payer status
Private†
40 (.28%)
REF
28 (.20%)
REF
60 (.43%)
REF
Public/Government
73 (.35%)
1.23 (.83-1.80)
88 (.42%)
2.11 (1.38-3.23)
122 (.58%)
1.37 (1.00-1.86)
Uninsured
57 (.83%)
2.93 (1.96-4.39)
33 (.48%)
2.42 (1.47-4.01)
18 (.26%)
.62 (.36-1.04)
† Patients with this characteristic served as the reference group; % of Total Sample is also known as “Absolute Risk”; CI denotes
confidence interval; Bold values indicate statistically significant values based on the CI; AYA= Adolescents & Young Adults; AI/AN=
American Indian/ Alaska Native; AA=African American
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